N4‐Acetylcytidine‐Mediated CD2BP2‐DT Drives YBX1 Phase Separation to Stabilize CDK1 and Promote Breast Cancer Progression
Advanced Science · 2025-04 · 12 (15)
DOI: 10.1002/advs.202411834 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.02.2025. Verfasst von Hongyu Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Y-Box-Binding Protein 1, RNA, Long Noncoding, CDC2 Protein Kinase. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Cultivation Plan for High level Scientific Research Projects of Xuzhou Medical University Affiliated Hospital, Postgraduate Research & Practice Innovation Program of Jiangsu Province.
Abstract (Originalsprache)
Long noncoding RNAs (lncRNAs) play critical roles in the initiation and progression of breast cancer. However, the specific mechanisms and biological functions of lncRNAs in breast cancer remain incompletely understood. Bioinformatics analysis identifies a novel lncRNA, CD2BP2‐DT, that is overexpressed in breast cancer and correlates with adverse clinicopathological features and poor overall survival. Both in vivo and in vitro experiments demonstrate that CD2BP2‐DT promotes proliferation of breast cancer cells. Mechanistically, NAT10 mediates the N4‐acetylcytidine (ac4C) modification of CD2BP2‐DT, enhancing its RNA stability and expression. More importantly, CD2BP2‐DT enhances the stability of CDK1 mRNA by mediating YBX1 phase separation, thereby promoting the proliferation of breast cancer cells. In conclusion, the lncRNA CD2BP2‐DT is identified as a crucial driver of breast cancer cell proliferation through the YBX1/CDK1 axis, highlighting its potential as a promising biomarker and therapeutic target for breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
- Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Institute of Digestive Diseases, Xuzhou Medical University, Xuzhou, 221002, China.
ORCID-Profile: Dongwei Zhang
Förderung
- National Natural Science Foundation of China
- Cultivation Plan for High level Scientific Research Projects of Xuzhou Medical University Affiliated Hospital
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
Zitieren
APA
Wang, H., Zhao, B., Zhang, J., Hu, Q., Zhou, L., Zhang, Y., Cai, Y., Qu, Y., Jiang, T., & Zhang, D. (2025). N4‐Acetylcytidine‐Mediated CD2BP2‐DT Drives YBX1 Phase Separation to Stabilize CDK1 and Promote Breast Cancer Progression. Advanced Science, 12(15). https://doi.org/10.1002/advs.202411834
Vancouver
Wang H, Zhao B, Zhang J, Hu Q, Zhou L, Zhang Y, et al. N4‐Acetylcytidine‐Mediated CD2BP2‐DT Drives YBX1 Phase Separation to Stabilize CDK1 and Promote Breast Cancer Progression. Advanced Science. 2025;12(15). doi:10.1002/advs.202411834
BibTeX
@article{Wang2025,
author = {Wang, Hongyu and Zhao, Bozhi and Zhang, Jiayu and Hu, Qunyu and Zhou, Linlin and Zhang, Yinghui and Cai, Yixin and Qu, Yuansong and Jiang, Tao and Zhang, Dongwei},
title = {N4‐Acetylcytidine‐Mediated CD2BP2‐DT Drives YBX1 Phase Separation to Stabilize CDK1 and Promote Breast Cancer Progression},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {15},
doi = {10.1002/advs.202411834}
}
EUVIMED